BioVectra Enters Into Agreement With Sandoz

BioVectra has signed agreements with Sandoz, whereunder Sandoz will commercialise and market
the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of
Taxotere developed by BioVectra. Docetaxel for injection (Taxotere) is an anti-mitotic chemotherapy
medication, used mainly for the treatment of breast, ovarian, neck, and non-small cell
lung cancers

Reportedly, the company has reached commercial marketing and supply agreements with Sandoz to
extend specific marketing rights within the US for the drug to Sandoz, and BioVectra believes this
is the first filing of a substantially complete ANDA containing a Paragraph IV certification for the
product.

Under the provisions of the Hatch-Waxman Act, it is expected that 180 days of sole
marketing exclusivity will be awarded, once final approval is obtained. The filing of the ANDA took
place in June, 2009.

While the specific terms of the agreement remain undisclosed, the two
companies have been cooperating toward the ANDA filing and preparing for a commercialisation strategy
together for much of 2009.

Dale Zajicek, chief operating officer for BioVectra, said: “We at
BioVectra are pleased to collaborate with Sandoz on providing the US market with a critical generic
option for Docetaxel. We look forward to a successful commercial program and providing an important
generic alternative to the market.”